Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma

Trial Profile

Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REC 2282 (Primary)
  • Indications Acute myeloid leukaemia; Advanced breast cancer; Biliary cancer; Carcinoma; Chronic lymphocytic leukaemia; Hodgkin's disease; Leukaemia; Lymphoma; Mantle-cell lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Testicular cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 Oct 2021 Results (n=57) of Pop PK analysis assessing whether or not use of body size-normalized dosing could reduce observed pharmacokinetic variability using data from two clinical studies NCT01129193 and NCT01798901 published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 21 Mar 2020 Results (n=55) of NCT01129193 (the FIH) and NCT01798901 assessing pharmacokinetic analysis for evaluation of oral absorption models and body size descriptors as potential sources of inter-individual variability in REC- 2282 PK, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 31 May 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top